Istari Oncology Honored as “Best Early Stage Product Development Company” in the Triangle Business Journal’s Life Sciences Awards

On May 20, 2021 Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapies for the treatment of solid tumors, reported that it was just awarded "Best Early Stage Product Development Company" within the Life Sciences award category by the Triangle Business Journal (Press release, Istari Oncology, MAY 20, 2021, View Source [SID1234580367]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Triangle Business Journal (TBJ) Life Sciences Awards recognize both individuals and research organizations in the Research Triangle region of North Carolina that are blazing trails and breaking ground in this field. The life sciences award category includes biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics, and many others. This year TBJ honored 16 winners – three individuals and 13 organizations – including Istari, in a ceremony held virtually earlier today.

"I’m really grateful for this award and for the Istari team to be honored by the Triangle Business Journal for all of their contributions," stated President and CEO, Matt Stober. "It serves as recognition of the hardworking team we have here at Istari Oncology and the unique immunotherapy we believe will change the treatment paradigm for cancer patients."

Istari’s lead immunotherapy candidate, PVSRIPO, is based on an attenuated version of the polio vaccine, originally developed through research at the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center. The therapy is currently being evaluated in multiple clinical trials across a range of solid tumors including glioblastoma and melanoma. PVSRIPO will also be evaluated in a "basket trial" that includes other solid tumors such as bladder cancer.